Sunitinib - Sarcomatrix Therapeutics
Latest Information Update: 14 Jan 2024
At a glance
- Originator Sarcomatrix Therapeutics
- Developer National Center for Advancing Translational Sciences; Sarcomatrix Therapeutics
- Class Amides; Antineoplastics; Ethylamines; Eye disorder therapies; Fluorobenzenes; Indoles; Pyrroles; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Colony stimulating factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Integrin alpha7 stimulants; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
- Research Cardiomyopathies
Most Recent Events
- 03 Jan 2024 Early research in Cardiomyopathies in USA (unspecified route), prior to January 2024 (Sarcomatrix Therapeutics pipeline, January 2024)
- 03 Jan 2024 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route), prior to January 2024 (Sarcomatrix Therapeutics pipeline, January 2024)